Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer to partner with Twist Bioscience to accelerate drug discovery
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
The company's "Library of Libraries", a collection of synthetic antibody libraries that harness innovative structural and developability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery.
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
Shareholders also approved an ordinary capital decrease of the share capital of Novartis AG in the amount of the share capital of Sandoz.
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/logo/gsk.png)
Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
More Pharma News ...
- Novartis completes acquisition of Chinook Therapeutics
- U.S. FDA Approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age
- Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics
- AbbVie announces European Commission approval of AQUIPTA® (atogepant) for the preventive treatment of migraine in adults
- Pfizer's ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
- Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
- Bill & Melinda Gates Foundation, Children's Investment Fund Foundation, Pfizer and Becton, Dickinson & Company expand partnership for greater access to injectable contraceptive for women in low- and lower-middle-income countries